Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: A nested case-control study

American Journal of Epidemiology

Volumn 177, Issue 1, 2013, Pages 3-13

  Touvier, Mathilde ^a,e   Fezeu, Léopold ^a   Ahluwalia, Namanjeet ^a   Julia, Chantal ^a   Charnaux, Nathalie ^b,c   Sutton, Angela ^b,c   Méjean, Caroline ^a   Latino Martel, Paule ^a   Hercberg, Serge ^a   Galan, Pilar ^a   Czernichow, Sébastien ^d  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL JEAN VERDIER   (France)

^c INSERM   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e NONE   (France)

Author keywords

breast neoplasms; C reactive protein; case control studies; intercellular adhesion molecule 1; neoplasms; prostatic neoplasms

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTATE SPECIFIC ANTIGEN; VASCULAR CELL ADHESION MOLECULE 1;

ABNORMALITY; BIOCHEMISTRY; BIOMARKER; BODY MASS; CANCER; CYTOLOGY; EXPERIMENTAL STUDY; HEALTH RISK; PLASMA; PROTEIN; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; OBESITY; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; THYROID CANCER;

ADIPONECTIN; ADIPOSITY; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CHEMOKINE CCL2; DOUBLE-BLIND METHOD; ENDOTHELIUM; FEMALE; HEALTH BEHAVIOR; HUMANS; INFLAMMATION; LEPTIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS;

FRANCE;

EID: 84871735031     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws359     Document Type: Article

References (54)

1. Barb D, Williams CJ, Neuwirth AK, et al. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(3):s858-s866.
2. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61(9):824-833.
3. Paz-Filho G, Lim EL, Wong ML, et al. Associations between adipokines and obesity-related cancer. Front Biosci. 2011; 16(1):1634-1650.
4. van Kilsdonk JW, van Kempen LC, van Muijen GN, et al. Soluble adhesion molecules in human cancers: sources and fates. Eur J Cell Biol. 2010;89(6):415-427.
5. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812.
6. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43(4):157-168.
7. O'Hanlon DM, Fitzsimons H, Lynch J, et al. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer. 2002;38(17):2252-2257.
8. Altomonte M, Fonsatti E, Lamaj E, et al. Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions. Breast Cancer Res Treat. 1999;58(1):19-23.
9. Basoglu M, Atamanalp SS, Yildirgan MI, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res. 2007;39(3):136-140.
10. Heikkila K, Silander K, Salomaa V, et al. C-reactive protein-associated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer. 2011;47(3):404-412.
11. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24(33):5216-5222.
12. Kaklamani VG, Wisinski KB, Sadim M, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA. 2008;300(13):1523-1531.
13. Moore SC, Leitzmann MF, Albanes D, et al. Adipokine genes and prostate cancer risk. Int J Cancer. 2009;124(4):869-876.
14. Pechlivanis S, Bermejo JL, Pardini B, et al. Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol. 2009;160(6):933-940.
15. Chen H, Hernandez W, Shriver MD, et al. ICAM gene cluster SNPs and prostate cancer risk in African Americans. Hum Genet. 2006;120(1):69-76.
16. Han W, Kang SY, Kang D, et al. Multiplex genotyping of 1107 SNPs from 232 candidate genes identified an association between IL1A polymorphism and breast cancer risk. Oncol Rep. 2010;23(3):763-769.
17. Kammerer S, Roth RB, Reneland R, et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res. 2004;64(24):8906-8910.
18. Guadagni F, Roselli M, Martini F, et al. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009;29(8):3321-3327.
19. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27(21):3437-3444.
20. Zhang GJ, Adachi I. Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol. 1999;14(1):71-77.
21. Prins RC, Rademacher BL, Mongoue-Tchokote S, et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol. 2012;30(1):33-37.
22. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):2217-2224.
23. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010; 28(16):2719-2726.
24. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20(1):15-26.
25. Lukanova A, Soderberg S, Kaaks R, et al. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(2):401-402.
26. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97(22):1688-1694.
27. Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2010;172(4):407-418.
28. Van Hemelrijck M, Jungner I, Walldius G, et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer. 2011;129(6):1485-1492.
29. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164(21):2335-2342.
30. Stamey TA. Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology. 1995;45(2):173-184.
31. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
32. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):221-233.
33. Schwartsburd PM. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev. 2003;22(1):95-102.
34. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545.
35. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32(5):471-482.
36. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004; 14(6):433-439.
37. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the Health Aging and Body Composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413-2418.
38. Trichopoulos D, Psaltopoulou T, Orfanos P, et al. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006;15(2):381-384.
39. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103(14): 1112-1122.
40. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer. 2006;42(6):704-707.
41. Pierce BL, Biggs ML, DeCambre M, et al. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control. 2009;20(7):1193-1203.
42. Stark JR, Li H, Kraft P, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009;124(11): 2683-2689.
43. Meyer MS, Penney KL, Stark JR, et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010;31(9):1597-1603.
44. Eklund CM, Tammela TL, Schleutker J, et al. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. Br J Cancer. 2009;100(12):1846-1851.
45. Arandi N, Talei A, Erfani N, et al. Intercellular adhesion molecule-1 genetic markers (+241G/A and +469A/G) in Iranian women with breast cancer. Cancer Genet Cytogenet. 2008;183(1):9-13.
46. Cox DG, Hankinson SE, Hunter DJ. Polymorphisms in the ICAM gene locus are not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(1):178-179.
47. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 2000;92(16):1329-1336.
48. Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res. 1999;59(20):5128-5132.
49. Gho YS, Kim PN, Li HC, et al. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res. 2001;61(10):4253-4257.
50. Curat CA, Miranville A, Sengenes C, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes. 2004;53(5):1285-1292.
51. Platz EA, De Marzo AM, Erlinger TP, et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate. 2004;59(4):393-400.
52. Lee SA, Kallianpur A, Xiang YB, et al. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2464-2470.
53. Linkov F, Gu Y, Arslan AA, et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur Cytokine Netw. 2009;20(1):21-26.
54. Knol MJ, Vandenbroucke JP, Scott P, et al. What do case-control studies estimate? Survey of methods and assumptions in published case-control research. Am J Epidemiol. 2008; 168(9):1073-1081.